LDHAL6CP

Across TCGA pan-cancer cohorts, LDHAL6CP RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of LDHAL6CP’s most consistent transcriptional readouts.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where LDHAL6CP RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LDHAL6CP is over-expressed in tumor.

PRAD, BRCA, and STAD are the cancer types where LDHAL6CP tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LDHAL6CP RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PRAD	All	All	+0.047	<.001	2	view →
BRCA	All	All	+0.003	.019	2	view →
STAD	Male	All	+0.005	.048	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

LDHAL6CP–PRAD

Open the PRAD breakdown →